TOP TEN perturbations for NM_000045 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000045
Selected probe(set): 206177_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000045 (206177_s_at) across 5339 perturbations tested by GENEVESTIGATOR:

hepatocyte (ESC) / HepaRG

Relative Expression (log2-ratio):-7.499588
Number of Samples:8 / 12
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control HepaRG
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):7.4796124
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

Hep-G2 / HepaRG

Relative Expression (log2-ratio):-7.1974335
Number of Samples:9 / 12
Experimental Hep-G2
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code:
Control HepaRG
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):-7.0533886
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

basal cell carcinoma study 3 / normal epidermal keratinocytes

Relative Expression (log2-ratio):6.8769054
Number of Samples:4 / 2
Experimental basal cell carcinoma study 3
Primary tumor tissue from the eyelid of patients with basal cell carcinoma (BCC).
Control normal epidermal keratinocytes
Normal human epidermal keratinocytes (NHEK) (Kurabo Ind., Ltd., Osaka, Japan) cultured in HuMedia-KB2 medium at 37?C in humidified air containing 5% CO2.

AML study 1 (t(15;17)(q22;q11-12)) / normal bone marrow sample

Relative Expression (log2-ratio):-6.0453568
Number of Samples:36 / 74
Experimental AML study 1 (t(15;17)(q22;q11-12))
Bone marrow samples of patients with acute promyelocytic leukemia [subtype of acute myeloid leukemia (AML)] with genetic aberration (t(15;17)(q22;q11-12)/PML-RAR? and variations).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

engineered skin substitute study 1 (late) / engineered skin substitute study 1 (early)

Relative Expression (log2-ratio):5.908519
Number of Samples:3 / 2
Experimental engineered skin substitute study 1 (late)
Human skin substitutes tissue samples collected after 14 days in culture.
Control engineered skin substitute study 1 (early)
Human skin substitutes tissue samples collected after 3 days in culture.

septic shock study 2 (24h) / normal blood sample

Relative Expression (log2-ratio):5.526085
Number of Samples:14 / 25
Experimental septic shock study 2 (24h)
Blood samples from intensive care unit patients 24 hours after severe septic shock (SAPS II-high). Severity was assessed using SAPS II score. Septic shock was defined as the combination of SIRS and an infection. To be diagnosed with SIRS patients had to show at least two of the following clinical situation: hypothermia (<36?C) or hyperthermia (>38?C), tachycardia (>90/min), tachypnea (>20 breaths/min) and/or arterial PCO2 of 32 mmHg or lower and/or mechanical ventilation, and leukocytosis (>12,000/mm3) or leukopenia (<4,000/mm3). Septic shock was defined as acute circulatory failure (systolic blood pressure <90 mmHg, mean arterial pressure <65 mmHg, or a reduction in systolic blood pressure >40 mmHg from baseline). In order to avoid confounding effects, patients with human immunodeficiency syndrome, hematologic malignancies evolving from insulin-dependent diabetes, dialyzed chronic renal failure, chronic liver disease stages III and more or patients receiving immunosuppressive therapy were excluded from the study. Other clinical characteristics of the group: non-survivor (28.5%), charlson median (1.3-3.8 %), SAPS II on admission median (49-63), duration length in ICU median (6-30), SOFA H6 (9-13), admission (surgery: 57.1%; medical: 42.9%); type of infection (community acquired: 64.29%; hospital acquired: 35.71%), suspected infection (Bacilli Gram (-): 64%; Cocci Gram (+):64%; Fungi: 0%), cell counts (white blood cells: 3.23-15.68 giga/L; lymphocytes: 0.4-1.33; polymorphonuclear cells: 2.5-12.61; monocytes: 0.19-0.66).
Control normal blood sample
Blood samples from healthy volunteers.

Merkel cell carcinoma study 3 (metastatic) / normal skin tissue

Relative Expression (log2-ratio):-5.4742136
Number of Samples:22 / 64
Experimental Merkel cell carcinoma study 3 (metastatic)
Metastatic tumor tissue from different metastatic sites (skin, lymph node, parotid gland) of patients with Merkel cell carcinoma of the skin.
Control normal skin tissue
Normal skin samples from healthy donors.

AML study 1 (t(11q23)) / normal bone marrow sample

Relative Expression (log2-ratio):-5.4380283
Number of Samples:38 / 74
Experimental AML study 1 (t(11q23))
Bone marrow samples of patients with acute myeloid leukemia (AML) with genetic aberration (t(11q23)/MLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.